Last reviewed · How we verify

moxifloxacin 0.5% eye drops

Allergan · FDA-approved active Small molecule

moxifloxacin 0.5% eye drops is a Fluoroquinolone antibiotic Small molecule drug developed by Allergan. It is currently FDA-approved for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer. Also known as: Vigamox®, Vigamox eye drops.

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription. Used for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer.

At a glance

Generic namemoxifloxacin 0.5% eye drops
Also known asVigamox®, Vigamox eye drops
SponsorAllergan
Drug classFluoroquinolone antibiotic
TargetBacterial DNA gyrase and topoisomerase IV
ModalitySmall molecule
Therapeutic areaOphthalmology / Infectious Disease
PhaseFDA-approved

Mechanism of action

As a broad-spectrum fluoroquinolone, moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This dual mechanism leads to rapid bactericidal activity against a wide range of gram-positive and gram-negative organisms. When formulated as eye drops, it achieves high local concentrations in ocular tissues to treat bacterial infections of the eye.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about moxifloxacin 0.5% eye drops

What is moxifloxacin 0.5% eye drops?

moxifloxacin 0.5% eye drops is a Fluoroquinolone antibiotic drug developed by Allergan, indicated for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer.

How does moxifloxacin 0.5% eye drops work?

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.

What is moxifloxacin 0.5% eye drops used for?

moxifloxacin 0.5% eye drops is indicated for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer, Post-operative ocular infection prophylaxis.

Who makes moxifloxacin 0.5% eye drops?

moxifloxacin 0.5% eye drops is developed and marketed by Allergan (see full Allergan pipeline at /company/allergan).

Is moxifloxacin 0.5% eye drops also known as anything else?

moxifloxacin 0.5% eye drops is also known as Vigamox®, Vigamox eye drops.

What drug class is moxifloxacin 0.5% eye drops in?

moxifloxacin 0.5% eye drops belongs to the Fluoroquinolone antibiotic class. See all Fluoroquinolone antibiotic drugs at /class/fluoroquinolone-antibiotic.

What development phase is moxifloxacin 0.5% eye drops in?

moxifloxacin 0.5% eye drops is FDA-approved (marketed).

What are the side effects of moxifloxacin 0.5% eye drops?

Common side effects of moxifloxacin 0.5% eye drops include Ocular irritation or discomfort, Conjunctival hyperemia, Taste perversion (from nasolacrimal drainage), Photophobia.

What does moxifloxacin 0.5% eye drops target?

moxifloxacin 0.5% eye drops targets Bacterial DNA gyrase and topoisomerase IV and is a Fluoroquinolone antibiotic.

Related